Clinical Trials in Sandton, South Africa

1 recruiting

Showing 17 of 7 trials

Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled283 locationsNCT06966700
Recruiting
Phase 3

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled299 locationsNCT06561386
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
Bristol-Myers Squibb76 enrolled48 locationsNCT06946797
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting
Phase 1Phase 2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Phase 2Phase 3

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

BioNTech SE4,292 enrolled134 locationsNCT05543616